Trial Profile

An Open-label Phase 1 Study to Evaluate the Safety of PF-08046045/SGN-35T in Adults With Advanced Malignancies

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 18 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SGN CD30C (Primary)
Indications Anaplastic large cell lymphoma; Diffuse large B cell lymphoma; Lymphoma; Peripheral T-cell lymphoma
Focus Adverse reactions
Sponsors Seagen

Most Recent Events

12 Jun 2025 Planned End Date changed from 30 Apr 2030 to 27 Jun 2029.
12 Jun 2025 Planned primary completion date changed from 30 Jun 2027 to 27 Jun 2028.
21 May 2025 Given protocol has been amended as above-1) Planned number of patients has been changed from 110 to 150. 2) sequential assignment has been implemented.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com